US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
CA2191455A1
(fr)
*
|
1994-06-20 |
1995-12-28 |
Wayne Vaccaro |
Composes d'azetidinone substitues utilises comme agent hypercholesterolemiant
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
DE69626128T2
(de)
*
|
1995-09-27 |
2003-11-27 |
Schering Corp., Kenilworth |
Stereoselektiver, mikrobieller reduktionsprozess
|
EP0766962A3
(fr)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Traitement de l'athérosclérose
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
BR9611401B1
(pt)
*
|
1995-10-31 |
2010-08-10 |
|
2-azetidinonas substituìdas com açúcar úteis como agentes hipocolesterolêmicos, composição farmacêutica e kit contendo as mesmas .
|
AU7472896A
(en)
*
|
1995-11-02 |
1997-05-22 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
|
EP0939632B1
(fr)
*
|
1996-02-23 |
2005-10-05 |
Eli Lilly And Company |
ANTAGONISTES DU RECEPTEUR DE LA VASOPRESSINE V1a NON PEPTIDYLIQUES
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
JP3640888B2
(ja)
*
|
1998-12-07 |
2005-04-20 |
シェーリング コーポレイション |
アゼチジノンの合成プロセス
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
EP1354604A1
(fr)
*
|
1998-12-23 |
2003-10-22 |
G.D. Searle LLC. |
Combinaisons pour indications cardiovasculaires
|
PL348503A1
(en)
*
|
1998-12-23 |
2002-05-20 |
Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
WO2000038721A1
(fr)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
|
EP1340510A1
(fr)
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de la protéine de transfert de l'ester de cholestéryle utilisées dans le cadre de troubles cardio-vasculaires
|
CA2356422C
(fr)
*
|
1998-12-23 |
2008-09-16 |
G.D. Searle Llc |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
|
AU776953B2
(en)
*
|
1998-12-23 |
2004-09-30 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
CA2356607A1
(fr)
*
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et de derives de l'acide fibrique utilisees dans le cadre de maladies cardio-vasculaires
|
CN1249250C
(zh)
|
1999-04-05 |
2006-04-05 |
先灵公司 |
用于制备1-(4-氟苯基)-3(R)-[3(S)-羟基-3-(4-氟苯基)丙基]-4(S)-(4-羟苯基)-2-β丙内酰胺的立体选择性微生物还原反应
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
AU2001247331A1
(en)
*
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
AU2002227240A1
(en)
*
|
2000-10-30 |
2002-05-15 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
EP1593670B1
(fr)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
2-Azétidinones substitués par hydroxy utilisés comme hypocholestérolémiants
|
EP1510521A1
(fr)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
2-azetidinones substitués par le sucre utilisés comme agents hypocholestérolémiants
|
HUP0302269A3
(en)
*
|
2000-12-20 |
2009-08-28 |
Schering Corp |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
BR0116325A
(pt)
*
|
2000-12-21 |
2003-10-14 |
Aventis Pharma Gmbh |
1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
CA2434488A1
(fr)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
Combinaisons d'acide nicotinique et de derives de ce dernier, inhibiteur(s) d'absorption de sterols et traitements de conditions vasculaires
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
AU2002247019C1
(en)
*
|
2001-01-26 |
2017-05-11 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
WO2002058696A2
(fr)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Utilisation de composes d'azetidinone substituee pour le traitement de la sitosterolemie
|
DK1353694T3
(da)
*
|
2001-01-26 |
2008-03-25 |
Schering Corp |
Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande
|
EP1541175A3
(fr)
*
|
2001-01-26 |
2006-04-12 |
Schering Corporation |
Combinaisons d'un inhibiteur de l'absorption de sterol avec un agent cardio-vasculaire pour le traitement des maladies cardio-vasculaires
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
EP1911462A3
(fr)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Combinaisons comprenant un inhibiteur d'absorption de stérol
|
JP2004521894A
(ja)
*
|
2001-01-26 |
2004-07-22 |
シェーリング コーポレイション |
胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
|
TWI291957B
(en)
*
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
DK1373230T3
(da)
|
2001-03-28 |
2005-11-07 |
Schering Corp |
Enantiselektiv syntese af azetidinon mellemprodukter
|
ATE345792T1
(de)
*
|
2001-05-25 |
2006-12-15 |
Schering Corp |
Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
SI1429756T1
(sl)
*
|
2001-09-21 |
2007-02-28 |
Schering Corp |
Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
WO2003026643A2
(fr)
*
|
2001-09-21 |
2003-04-03 |
Schering Corporation |
Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
|
WO2003040127A1
(fr)
*
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Composes benzothiepine mono- et di-fluores en tant qu'inhibiteurs du transport d'acides biliaires a co-dependance sodique apicale (asbt) et de reprise de taurocholate
|
IL161741A0
(en)
*
|
2001-11-09 |
2005-11-20 |
Atherogenics Inc |
Methods of reversing and preventingcardiovascular pathologies
|
MXPA04005864A
(es)
*
|
2001-12-19 |
2004-10-29 |
Atherogenics Inc |
Derivados de charcona y su uso para tratar enfermedades.
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
JP2005521653A
(ja)
|
2002-01-17 |
2005-07-21 |
ファルマシア コーポレイション |
先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
|
US20050123580A1
(en)
*
|
2002-02-28 |
2005-06-09 |
Burris Thomas P. |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
PL374860A1
(en)
|
2002-07-09 |
2005-11-14 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
CN1678296A
(zh)
*
|
2002-07-30 |
2005-10-05 |
卡里凯昂公司 |
依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
|
US20040181075A1
(en)
*
|
2002-12-19 |
2004-09-16 |
Weingarten M. David |
Process of making chalcone derivatives
|
US7192944B2
(en)
*
|
2003-03-07 |
2007-03-20 |
Schering Corp. |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
EP1601669B1
(fr)
|
2003-03-07 |
2008-12-24 |
Schering Corporation |
Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
|
ES2311806T3
(es)
*
|
2003-03-07 |
2009-02-16 |
Schering Corporation |
Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
|
EP1626954A2
(fr)
*
|
2003-05-05 |
2006-02-22 |
Ranbaxy Laboratories, Ltd. |
Procede pour la preparation de trans-isomeres de derives de diphenylazetidinone
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
NZ543741A
(en)
*
|
2003-05-30 |
2009-10-30 |
Ranbaxy Lab Ltd |
Substituted pyrrole derivatives and their use as HMG-Co inhibitors
|
WO2005000217A2
(fr)
*
|
2003-06-06 |
2005-01-06 |
Merck & Co., Inc. |
Polytherapie permettant de traiter la dyslipidemie
|
WO2005009951A2
(fr)
*
|
2003-07-24 |
2005-02-03 |
Merck & Co., Inc. |
Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation
|
WO2005009955A1
(fr)
*
|
2003-07-31 |
2005-02-03 |
Hetero Drugs Limited |
Polymorphes de l'ezetimibe
|
EP1522541A1
(fr)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Nouveaux composés hypocholesterolémiques
|
WO2005042692A2
(fr)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes
|
EP1918000A2
(fr)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
|
WO2005046797A2
(fr)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
|
JP2007520453A
(ja)
*
|
2003-11-10 |
2007-07-26 |
マイクロビア インコーポレーテッド |
4−ビアリーリル−1−フェニルアゼチジン−2−オン
|
AU2003282384A1
(en)
*
|
2003-11-24 |
2005-06-08 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
WO2005061452A1
(fr)
*
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
|
WO2005062824A2
(fr)
|
2003-12-23 |
2005-07-14 |
Merck & Co., Inc. |
Composes anti-hypercholesterolemie
|
CA2553769C
(fr)
*
|
2004-01-16 |
2011-01-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) et procedes pour identifier des ligands de ceux-ci
|
ES2399721T5
(es)
*
|
2004-03-05 |
2016-05-25 |
Univ Pennsylvania |
Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
AU2005245124A1
(en)
*
|
2004-05-21 |
2005-12-01 |
Sanofi-Aventis Deutschland Gmbh |
Method for producing 1,4-diphenyl azetidinone derivatives
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
WO2006026273A2
(fr)
*
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Procede pour traiter l'atherosclerose, la dyslipidemie et les etats pathologiques associes
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
PE20060594A1
(es)
*
|
2004-09-09 |
2006-08-18 |
Novartis Ag |
Composicion farmaceutica que contiene un agonista de ppar
|
CA2581596A1
(fr)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinaisons d'azetidinones substituees et d'antagonistes cb<sb>1</sb>
|
ES2435790T3
(es)
|
2004-12-03 |
2013-12-23 |
Intervet International B.V. |
Piperazinas sustituidas como antagonistas de CB1
|
CA2592350A1
(fr)
*
|
2004-12-15 |
2006-06-22 |
Schering Corporation |
Essais fonctionnels pour l'identification d'inhibiteurs d'absorption du cholesterol
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
EP1865947A1
(fr)
*
|
2005-04-04 |
2007-12-19 |
Pontificia Universidad Catolica de Chile |
Utilisation d'ezetimibe pour prevenir et traiter des calculs biliaires de cholesterol
|
TW200726746A
(en)
*
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
CA2608108A1
(fr)
*
|
2005-05-09 |
2006-11-16 |
Microbia, Inc. |
Agents de couplage de benzenephosphonate organometallique
|
KR20080017345A
(ko)
*
|
2005-05-11 |
2008-02-26 |
마이크로비아 인코포레이티드 |
페놀성 4-비페닐일아제티딘-2-온의 제조방법
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
EA200702614A1
(ru)
*
|
2005-05-25 |
2008-04-28 |
Майкробиа, Инк. |
Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
|
JP2008543837A
(ja)
*
|
2005-06-15 |
2008-12-04 |
メルク エンド カムパニー インコーポレーテッド |
抗高コレステロール血症化合物
|
CN101243072A
(zh)
*
|
2005-06-20 |
2008-08-13 |
先灵公司 |
用作组胺h3拮抗剂的哌啶衍生物
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
RU2008102236A
(ru)
*
|
2005-06-22 |
2009-07-27 |
РЕДДИ Манне САТЬЯНАРАЯНА (IN) |
Улучшенный способ получения эзетимиб
|
EP1741427A1
(fr)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
WO2007030721A2
(fr)
*
|
2005-09-08 |
2007-03-15 |
Teva Pharmaceutical Industries Ltd. |
Procedes pour preparer (3r,4s)-4-((4-benzyloxy)phenyle)-1-(4-fluorophenyle)-3-((s)-3-(4-fluorophenyle)-3-hydroxypropyle)-2-azetidinone, un intermediaire pour la synthese de l'ezetimibe
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
CN101291662A
(zh)
|
2005-10-21 |
2008-10-22 |
诺瓦提斯公司 |
肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
|
US8026377B2
(en)
*
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
HU0501164D0
(en)
*
|
2005-12-20 |
2006-02-28 |
Richter Gedeon Vegyeszet |
New industrial process for the production of ezetimibe
|
BRPI0620255A2
(pt)
*
|
2005-12-21 |
2011-11-08 |
Schering Corp |
uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
|
DE602006009845D1
(de)
*
|
2005-12-22 |
2009-11-26 |
Medichem Sa |
Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
|
CA2637565A1
(fr)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Modulateurs de recepteurs de cannibinoides
|
MX2008010235A
(es)
*
|
2006-02-16 |
2008-10-23 |
Kotobuki Pharmaceutical Co Ltd |
Metodo para producir alcohol opticamente activo.
|
US7910698B2
(en)
*
|
2006-02-24 |
2011-03-22 |
Schering Corporation |
NPC1L1 orthologues
|
MX2008011418A
(es)
*
|
2006-03-06 |
2008-09-22 |
Teva Pharma |
Composiciones de ezetimibe.
|
AR059838A1
(es)
*
|
2006-03-14 |
2008-04-30 |
Ranbaxy Lab Ltd |
Formulaciones para dosis estabilizantes de estatina
|
US20080032964A1
(en)
*
|
2006-04-10 |
2008-02-07 |
Kansal Vinod K |
Process for the synthesis of azetidinone
|
TW200811098A
(en)
*
|
2006-04-27 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
WO2008010087A2
(fr)
*
|
2006-07-14 |
2008-01-24 |
Ranbaxy Laboratories Limited |
FORMES POLYMORPHES D'UN INHIBITEUR DE LA HMG-CoA-RÉDUCTASE ET LEURS UTILISATIONS
|
JP2009503119A
(ja)
*
|
2006-08-29 |
2009-01-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
(3r,4s)−4−(4−ヒドロキシ保護−フェニル)−1−(4−フルオロフェニル)−3−[3−(4−フルオロフェニル)−3−オキソプロピル]アゼチジン−2−オンを精製する方法
|
EP2059241A1
(fr)
*
|
2006-09-05 |
2009-05-20 |
Schering Corporation |
Compositions pharmaceutiques pour un traitement des lipides et dans le traitement de l'athérosclérose et de la stéatose hépatique
|
CN101528227A
(zh)
*
|
2006-09-15 |
2009-09-09 |
先灵公司 |
氮杂环丁酮衍生物及其使用方法
|
CN101583612A
(zh)
*
|
2006-09-15 |
2009-11-18 |
先灵公司 |
治疗脂质代谢障碍的氮杂环丁酮衍生物
|
JP2010503679A
(ja)
|
2006-09-15 |
2010-02-04 |
シェーリング コーポレイション |
疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
|
US20080070890A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Burnett Duane A |
Spirocyclic Azetidinone Compounds and Methods of Use Thereof
|
CA2663500A1
(fr)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Derives d'azetidine spiro-condenses convenant pour le traitement de la douleur, du diabete et des troubles du metabolisme des lipides
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
WO2008085300A1
(fr)
*
|
2006-12-20 |
2008-07-17 |
Merck & Co., Inc. |
Composé anti-hypercholestérolémique
|
EP1939174A1
(fr)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Complexe d'inclusion d'ezetimibe et une cyclodextrine et procédés pour son préparation
|
JP2010513534A
(ja)
*
|
2006-12-21 |
2010-04-30 |
エージェリオン ファーマシューティカルズ, インコーポレイテッド |
Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
|
EA017349B1
(ru)
*
|
2007-01-24 |
2012-11-30 |
Крка |
Способ получения эзетимиба и его производных
|
WO2008096372A2
(fr)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Procédé de préparation de l'ézétimibe extrêmement pur au moyen de nouveaux intermédiaires
|
WO2008104875A1
(fr)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones comme inhibiteurs d'absorption de cholestérol
|
EP2133347A4
(fr)
|
2007-03-06 |
2010-03-17 |
Teijin Pharma Ltd |
Dérivés de 1-biarylazétidinone
|
CL2008000684A1
(es)
|
2007-03-09 |
2008-08-01 |
Indigene Pharmaceuticals Inc |
Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
|
WO2008123953A1
(fr)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Composé anti-hypercholestérolémique
|
WO2008130616A2
(fr)
*
|
2007-04-19 |
2008-10-30 |
Schering Corporation |
Diaryl morpholines comme modulateurs des récepteurs cb1
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
JP2010529148A
(ja)
*
|
2007-06-07 |
2010-08-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
エゼチミブ製造のための還元方法
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
BRPI0814806A2
(pt)
*
|
2007-06-28 |
2015-02-03 |
Intervet Int Bv |
Pirazinas substituídas como antagonistas de cb1
|
JP2010531874A
(ja)
*
|
2007-06-28 |
2010-09-30 |
インターベット インターナショナル ベー. フェー. |
Cb1アンタゴニストとしての置換ピペラジン
|
WO2009016358A2
(fr)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Compositions pharmaceutiques et leur procédé de préparation
|
WO2009024889A2
(fr)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
|
WO2009027785A2
(fr)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
Composés pharmaceutiques et dérivés
|
WO2009032264A1
(fr)
*
|
2007-08-30 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Procédés de préparation d'intermédiaires d'ézétimibe par réduction microbienne
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2217214B1
(fr)
|
2007-12-10 |
2017-07-19 |
ratiopharm GmbH |
Formulation pharmaceutique comprenant de l'ézétimibe
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(fr)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Procédé et composition d'ézétimibe
|
CA2724873A1
(fr)
*
|
2008-06-06 |
2009-12-10 |
Nicox S.A. |
Compositions comprenant de l'ester 4-(nitrooxy)butylique d'atorvastatine et un medicament hypolipidemique
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
SI2329014T1
(sl)
|
2008-08-29 |
2015-01-30 |
Codexis, Inc. |
Polipeptidi ketoreduktaze za stereoselektivno produkcijo (4s)-3(5s)-5(4-fluorofenil)-5-hidroksipentanoil)-4-fenil-1,3-oksazolidin -2-ona
|
MX2011005077A
(es)
|
2008-11-14 |
2011-05-25 |
Bomi P Framroze |
Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis.
|
EP2204170A1
(fr)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Composition pharmaceutique comprenant ézétimide et simvastatine
|
WO2010075068A1
(fr)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Dérivés de pyridopyrimidine et leurs procédés d'utilisation
|
EP2379562A1
(fr)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
|
EP2216016A1
(fr)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
|
CA2754384A1
(fr)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Compositions pharmaceutiques hypocholesterolemiques
|
ATE536172T1
(de)
|
2009-03-13 |
2011-12-15 |
Sanovel Ilac Sanayi Ve Ticaret As |
Ezetimibzusammensetzungen
|
EP2414326B1
(fr)
|
2009-03-31 |
2017-12-20 |
Lupin Limited |
Intermediaires utilises dans la preparation de 1,4-diphenylazetidinone
|
EP2414529A2
(fr)
|
2009-04-01 |
2012-02-08 |
Matrix Laboratories Ltd |
Procédé enzymatique pour la préparation de la (s)-5-(4-fluorophényl)-5-hydroxy-1-morpholin-4-yl-pentan-1-one, un intermédiaire de l'ézétimibe et la conversion ultérieure en ézétimibe
|
WO2011002422A2
(fr)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Formulation pharmaceutique améliorant la solubilité
|
EP2448919A2
(fr)
|
2009-07-02 |
2012-05-09 |
Mahmut Bilgic |
Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
|
WO2011002424A2
(fr)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Préparation pharmaceutique améliorant la solubilité et la stabilité
|
CN101993403B
(zh)
*
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
ES2575560T3
(es)
|
2009-08-19 |
2016-06-29 |
Codexis, Inc. |
Polipéptidos cetorreductasa para preparar fenilefrina
|
AU2011220748B2
(en)
|
2010-02-24 |
2015-11-05 |
Relypsa, Inc. |
Amine polymers for use as bile acid sequestrants
|
BR112012021444A2
(pt)
|
2010-02-24 |
2016-05-31 |
Relypsa Inc |
polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
|
JP5964247B2
(ja)
|
2010-02-24 |
2016-08-03 |
レリプサ, インコーポレイテッド |
胆汁酸捕捉剤として使用するためのポリイミダゾール
|
EP2368543A1
(fr)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
|
PT3205351T
(pt)
|
2010-04-23 |
2023-06-28 |
Alexion Pharma Inc |
Enzima de doença de armazenamento lisossomal
|
EP2566497B1
(fr)
|
2010-05-04 |
2015-07-29 |
Codexis, Inc. |
Biocatalyseurs pour la synthèse d'ézétimibe
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
CN105457018A
(zh)
|
2010-09-09 |
2016-04-06 |
辛那杰瓦生物制药股份有限公司 |
使用溶酶体酸性脂肪酶来治疗患者的溶酶体酸性脂肪酶缺乏
|
HUE030062T2
(en)
|
2010-11-08 |
2017-04-28 |
Albireo Ab |
IBAT inhibitors for the treatment of liver diseases
|
PT2637646T
(pt)
|
2010-11-08 |
2016-08-17 |
Albireo Ab |
Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
|
WO2012076030A1
(fr)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Procédé de préparation de composés intermédiaires utiles dans la préparation de l'ézétimibe
|
WO2012112681A1
(fr)
|
2011-02-15 |
2012-08-23 |
Shire Human Genetic Therapies, Inc. |
Procédés de traitement d'un déficit en lipase acide lysosomale
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(fr)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Procédé amélioré pour la préparation d'ézétimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
PL2844233T3
(pl)
|
2012-05-01 |
2020-09-07 |
Althera Life Sciences, Llc |
Preparat w postaci tabletki do stosowania doustnego składający się ze stałego połączenia rosuwastatyny i ezetymibu w leczeniu hiperlipidemii i chorób sercowo-naczyniowych
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(fr)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Nouveau procédé de préparation d'intermédiaires d'ézétimibe
|
WO2015066252A1
(fr)
|
2013-11-04 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Composés antagonistes du récepteur du glucagon, compositions correspodantes et méthodes d'utilisation
|
US9926269B2
(en)
|
2013-12-18 |
2018-03-27 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
CN105294426B
(zh)
*
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
CN114099496A
(zh)
|
2015-03-13 |
2022-03-01 |
艾斯柏伦治疗公司 |
含etc1002和依泽替米贝的组合及治疗方法
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
CN109791797B
(zh)
|
2016-12-05 |
2023-05-02 |
智慧芽信息科技(苏州)有限公司 |
在大数据库中根据化学结构相似性搜索和显示可用信息的系统、装置和方法
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(fr)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Composition pharmaceutique comprenant de l'ézétimibe
|
EP3740653A4
(fr)
|
2018-01-16 |
2021-10-20 |
Q.E.D. Environmental Systems, Inc. |
Système de surveillance de niveau de fluide et procédé incorporant un système de capteur de pression ayant un sac gonflable/repliable
|
EP3942047A1
(fr)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Traitement de niveaux de lipides accrus avec des inhibiteurs de protéine d'activation de clivage de protéine de liaison d'élément régulateur de stérol (scap)
|
CN113727732B
(zh)
|
2019-03-20 |
2023-08-08 |
雷杰纳荣制药公司 |
用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
|
WO2021019499A1
(fr)
|
2019-07-31 |
2021-02-04 |
TECNIMEDE - Sociedade Técnico-medicinal, SA |
Compositions solides orales à libération immédiate à unités multiples, procédés et utilisations de celles-ci
|
WO2022023206A1
(fr)
|
2020-07-27 |
2022-02-03 |
Krka, D.D., Novo Mesto |
Comprimé bicouche comprenant de l'ézétimibe et de l'atorvastatine
|
AU2022291920A1
(en)
*
|
2021-06-17 |
2023-12-21 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Hybutimibe intermediate and preparation method therefor
|
WO2023275715A1
(fr)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Métabolites de modulateurs sélectifs du récepteur des androgènes
|
WO2024151311A1
(fr)
|
2023-01-09 |
2024-07-18 |
Esperion Therapeutics, Inc. |
Méthodes de traitement utilisant de l'acide bempédoïque
|